RMC No. 51-2022 updates the CREATE Act VAT-exempt medicine list for COVID-19, hypertension, and a corrected cancer medicine entry.
Businesses dealing in covered medicines should immediately check whether their invoicing, VAT treatment, product master files, and pharmacy or distribution records reflect the latest VAT-exempt medicine list recognized for CREATE Act purposes. RMC No. 51-2022 confirms an update endorsed by the Food and Drug Administration to the List of VAT-Exempt Medicines under Republic Act No. 11534, otherwise known as the CREATE Act. The update matters now because sellers, distributors, hospitals, clinics, pharmacies, and corporate buyers of covered medicines must determine whether specific medicines for COVID-19 treatment and hypertension should be treated as VAT-exempt, and whether the corrected cancer medicine entry affects prior or current tax handling.
What RMC No. 51-2022 Changed
RMC No. 51-2022 publishes the endorsement from the Food and Drug Administration of the Department of Health updating the List of VAT-Exempt Medicines under the CREATE Act. The update covers certain medicines for COVID-19 treatment and hypertension, and also corrects a medicine for cancer. For businesses and tax teams, the practical effect is that the BIR has made the FDA-endorsed update part of the tax compliance reference for determining which listed medicines may be sold, purchased, recorded, and invoiced as VAT-exempt.
The single most important compliance point is that VAT exemption does not apply generically to every medicine used for COVID-19, hypertension, or cancer. It applies only to medicines included in the VAT-exempt list as updated through the proper regulatory process. RMC No. 51-2022 therefore requires taxpayers to review the specific medicine entries covered by the FDA endorsement, rather than relying on broad disease categories or commercial descriptions alone.
This issuance is especially relevant to searches for VAT-exempt medicines Philippines, CREATE Act VAT exemption medicines, BIR VAT exempt medicine list, COVID-19 treatment VAT exemption, hypertension medicine VAT exemption, and cancer medicine VAT correction. These are the terms accountants and compliance teams should associate with RMC No. 51-2022 when updating their tax treatment and documentation.
Who Is Affected
The taxpayers most directly affected are pharmaceutical companies, medicine distributors, drugstores, hospital pharmacies, clinics, healthcare institutions, importers, wholesalers, and retailers that sell or purchase medicines falling within the updated FDA-endorsed list. The issuance also affects corporate accounting departments and tax managers that process purchases of covered medicines for employee health programs, clinic operations, or medical benefit arrangements.
VAT-registered sellers must pay particular attention because the classification of a medicine as VAT-exempt changes how the sale is invoiced and reported. A covered VAT-exempt sale should not be treated in the same way as a regular VATable sale. If a medicine is included in the updated VAT-exempt list, the seller must ensure that the transaction is properly reflected as VAT-exempt in its sales documentation, accounting system, and tax returns.
Purchasers are also affected. A buyer that receives an invoice for a medicine covered by the updated list should review whether VAT was improperly imposed. For institutional buyers, this is not merely a pricing issue. It can affect input VAT accounting, expense recording, reimbursement computations, and supplier compliance review.
Key Compliance Requirements and Effective Date
RMC No. 51-2022 was issued on April 21, 2022. The issuance publishes the FDA letter dated April 21, 2022 endorsing updates to the VAT-exempt medicines list. Businesses should treat April 21, 2022 as the relevant issuance date for compliance review, subject to the specific rules and administrative implementation applicable to the listed medicines.
The key compliance requirement is documentary and systems alignment. Taxpayers should identify whether any products they manufacture, import, distribute, sell, dispense, procure, or reimburse are among the medicines covered by the updated list. If so, the taxpayer should confirm that the product description, medicine classification, tax code in the point-of-sale or enterprise resource planning system, and invoice treatment are consistent with the VAT-exempt status recognized through the BIR issuance.
For sellers, the practical compliance steps include updating product tax mapping, training billing and pharmacy personnel, checking whether VAT is automatically added at checkout or invoicing, and confirming that VAT-exempt sales are separately tracked. For buyers, the practical steps include reviewing supplier invoices, checking whether VAT was passed on for covered medicines, and ensuring that no improper input VAT claim is recorded where the purchase should have been VAT-exempt.
Because the issuance also corrects a medicine for cancer, taxpayers should not assume that prior internal medicine lists remain accurate. A correction may affect how a medicine is searched, described, matched, or validated for VAT exemption purposes. Businesses should therefore compare their existing medicine master list against the updated FDA-endorsed list and correct any inconsistent tax treatment.
Penalties and Risks for Non-Compliance
RMC No. 51-2022 itself publishes the FDA-endorsed update and does not state a special penalty schedule in the summarized issuance. However, ordinary tax risks remain significant. A seller that incorrectly treats a covered medicine as VATable may overcharge VAT and create disputes with customers, while a seller that incorrectly treats a non-covered medicine as VAT-exempt may face deficiency VAT exposure if the BIR later determines that the exemption was improperly applied.
The compliance risk is therefore two-sided. Over-application of VAT exemption may result in deficiency assessments, surcharge, interest, and compromise penalties under general tax rules. Under-application of VAT exemption may create refund, credit, pricing, or customer-relation issues, particularly for hospitals, pharmacies, and institutional procurement departments that handle large volumes of medicine transactions.
Taxpayers should also consider audit trail risk. During a BIR examination, it may not be enough to state that a medicine is for COVID-19 treatment, hypertension, or cancer. The taxpayer should be able to show that the medicine is covered by the applicable VAT-exempt list as updated through RMC No. 51-2022 and the FDA endorsement. This makes product-level documentation critical.
Practical Steps for Businesses
First, obtain the current internal product list for all medicines sold, purchased, dispensed, or reimbursed by the business. Second, isolate medicines connected with COVID-19 treatment, hypertension, and cancer. Third, compare those medicines against the FDA-endorsed update recognized through RMC No. 51-2022. Fourth, update VAT codes in accounting, invoicing, pharmacy, and point-of-sale systems. Fifth, review invoices issued or received from the relevant period to identify whether VAT was charged or claimed inconsistently.
Pharmaceutical sellers and distributors should also coordinate among tax, regulatory, sales, and IT teams. The tax department may know the VAT rule, while the regulatory team may know the FDA product details, and the billing team may control the actual invoice treatment. RMC No. 51-2022 is exactly the type of issuance where tax compliance can fail because the legal rule is not properly translated into product-level system settings.
For hospitals, clinics, and corporate buyers, the recommended action is to review supplier invoices for covered medicines and request clarification where VAT appears to have been imposed on a medicine that should be VAT-exempt. Where the medicine entry has been corrected, buyers should verify the correct description and tax treatment before recording purchases or processing reimbursements.
Why This Matters for CFOs, Accountants, and Healthcare Businesses
RMC No. 51-2022 is not merely a technical publication. It affects pricing, invoice compliance, tax reporting, procurement review, and audit defense. In industries where medicine transactions are high-volume and system-driven, even a narrow VAT exemption update can create repeated errors if product tax mapping is not corrected quickly.
CFOs and tax managers should treat the issuance as a prompt to update internal controls for VAT-exempt medicines under the CREATE Act. The safer approach is to maintain a documented review trail showing when the business checked the updated list, who approved the tax code changes, and how affected invoices or transactions were handled.
ASG Law Can Assist with BIR Compliance on VAT-Exempt Medicines
Ablola, Saribong & Gueco assists businesses, healthcare companies, pharmacies, distributors, and corporate taxpayers in reviewing BIR issuances, VAT treatment, invoicing practices, and tax audit exposure. For RMC No. 51-2022, our team can help determine whether specific medicine transactions are covered by the updated VAT-exempt list, review invoice treatment, and prepare practical compliance steps for accounting and operations teams.
If your company sells, distributes, purchases, or reimburses medicines affected by the CREATE Act VAT exemption rules, now is the time to review your tax treatment before a BIR audit or supplier dispute arises. For assistance with VAT-exempt medicines, BIR compliance, and Philippine tax advisory services, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.